Yahoo Finance • 4 days ago
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in t... Full story
Yahoo Finance • 9 days ago
(RTTNews) - A wave of after-hours activity swept through select biotech and medical device names Thursday, with several micro- and mid-cap stocks posting sharp gains following session-end catalysts, volume spikes, or pipeline updates. Belo... Full story
Yahoo Finance • 10 days ago
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story
Yahoo Finance • 23 days ago
* Reviva Pharmaceuticals (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) announced [https://seekingalpha.com/pr/20238101-reviva-pharmaceuticals-holdings-inc-announces-pricing-of-9-million-public-offering] on Thursday a public offeri... Full story
Yahoo Finance • 23 days ago
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in... Full story
Yahoo Finance • 23 days ago
* Reviva Pharmaceuticals Holdings (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) on Thursday said it intends to offer shares of its common stock and warrants to purchase shares of common stock in a public offering. * All of the s... Full story
Yahoo Finance • 23 days ago
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in... Full story
Yahoo Finance • 2 months ago
Key Points Net loss (GAAP) narrowed to $6.1 million in Q2 2025, a 22.8% improvement from the prior-year period, driven by reduced research and development spending. No product revenue reported; The company’s clinical-stage focus and cash... Full story
Yahoo Finance • 2 months ago
* Reviva Pharmaceuticals press release [https://seekingalpha.com/pr/20202002-reviva-reports-second-quarter-2025-financial-results-and-recent-business-highlights] (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]): Q2 GAAP EPS of -$0.12... Full story
Yahoo Finance • 2 months ago
– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized do... Full story
Yahoo Finance • 4 months ago
* Reviva Pharmaceuticals Holdings (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) on Thursday announced the pricing of its public offering with existing and new healthcare focused institutional investors. * The offering entails th... Full story
Yahoo Finance • 4 months ago
CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in t... Full story
Yahoo Finance • 4 months ago
Investing.com -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) stock tumbled 23.4% after the late-stage pharmaceutical company announced its intention to offer shares of common stock and warrants in a public offering. The company, w... Full story
Yahoo Finance • 4 months ago
CUPERTINO, Calif. - Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH), a pharmaceutical company with a market capitalization of $35.6 million, announced today its intention to offer shares of common stock and warrants in a public offerin... Full story
Yahoo Finance • 4 months ago
* Reviva Pharmaceuticals (NASDAQ:RVPH [https://seekingalpha.com/symbol/RVPH]) plans to offer common stock or equivalents and warrants in a public offering. * All securities in the offering will be sold by the company. * Proceeds will... Full story
Yahoo Finance • 4 months ago
CUPERTINO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in t... Full story
Yahoo Finance • 4 months ago
– Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated with low rates of adverse events and discontinuation – – Brilaroxazine improved multiple neuroinfl... Full story
Yahoo Finance • 5 months ago
– 446 participants completed the brilaroxazine long-term open-label extension (OLE) trial with 156 completing one-year and 301 completing six months of treatment – – Full data set from RECOVER OLE highlighting clinical response, safety, e... Full story
Yahoo Finance • 6 months ago
– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-20... Full story
Yahoo Finance • 6 months ago
CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous... Full story